Hepatic Diseases and Disorders

Featured Article
Patients with viral hepatitis-related cirrhosis are known to be at increased risk of hepatocellular carcinoma and cholangiocarcinoma, and early detection greatly improves outcomes. Yet far too few patients are not being screened, said Amit Singal, MD, from UT-Southwestern Medical Center, at the American Association for the Study of Liver Diseases Annual Meeting.
Early recognition and management of acute kidney injury are critical to optimize outcomes among patients with advanced liver disease.
Big decreases in the cost of gene sequencing is making the delivery of precision care to patients with liver disease increasingly feasible, says Scott L. Friedman, MD, at the virtual 2020 Liver Meeting.
Gastroenterologists and hepatologists must carefully assess and interpret studies of iron deposition to guide treatment of patients with both genetic and secondary hemochromatosis, Vinday Sundaram, MD, explained at the American Association for the Study of Liver Diseases.
Delivering supportive care that improves clinical outcomes and quality of life to patients with end-stage liver disease requires eliminating barriers and creating effective multidisciplinary teams, Victor J. Navarro, MD, told the AASLD annual meeting.
The director of the National Institute on Allergies and Infectious Diseases, Dr Anthony Fauci, led off a panel that reviewed the impact of COVID-19 on liver function and on patients with liver disease at the American Association for the Study of Liver Diseases meeting.
While it has proven safe and effective for treating recurrent or refractory Clostridiodes difficile infections in patients with inflammatory bowel disease, fecal microbiota transplantation may also improve outcomes for patients with nonalcoholic fatty liver disease. New research hints at an answer.
It has been unclear whether nonalcoholic fatty liver disease is directly related to cardiovascular disease or whether this relationship is confounded by metabolic factors of NAFLD and CVD. What do you think?
In a study presented at the 21st Annual Harvard Nutrition and Obesity Symposium, Kathleen E. Corey, MD, spoke about the risk factors for cardiovascular disease and MACE among patients with NAFLD.
Nonalcoholic steatohepatitis is a potentially progressive form of nonalcoholic fatty liver disease. Recent research, which was discussed at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD, shows an increasing burden of these diseases worldwide. Speaker Zobair Younossi, MD, from Inova Fairfax Medical Campus, shed light.
It is common for patients with nonalcoholic fatty liver disease to progress to nonalcoholic steatohepatitis. Do you know which factors contribute to progression? Take our pop quiz to find out!